SPEAKER
Prof Patrizia AGOSTINIS
Head of the Cell Death Research & Therapy
laboratory, Department of Cellular and
Molecular Medicine, University of Leuven, KU
Leuven, Belgium
HOST:
UniLu and LIH
RESPONSIBLE LIH SCIENTISTS:
Thomas Sauter
(thomas.sauter@uni.lu)
Bassam Janji
(bassam.janji@lih.lu)
www.lih.lu
www.uni.lu
|
HARNESSING IMMUNOGENIC CELL DEATH FOR
IMMUNOTHERAPY AGAINST CANCER; FROM TRANSLATIONAL
MEDICINE TO MOLECULAR MEDIATORS
ABSTRACT
|
In recent times, crucial cellular processes
supporting cancer cell growth and
regulating the crosstalk between cancer
cells with stromal cells, the major hallmarks
of cancer, have been delineated,
which are expected to facilitate anticancer
therapy development. Therapeutic
induction of endoplasmic reticulum (ER)
stress is emerging as a strategy to target
multiple hallmarks of cancer, and several
ER stress-inducing therapies exhibit a
positive clinical profile in cancer patients.
Recently, therapy-induced ER
stress has been shown to be a quintessential
cancer cell-autonomous feature
|
to elicit immunogenic cancer cell death
(ICD). In therapeutic terms, ICD is the
most favorable type of cell death since it
combines efficient cancer cell killing (a
cell autonomous feature) with the ability
to activate the immune system against
cancer (cell non-autonomous features),
therefore resetting two key hallmarks of
cancer; resistance to cell death and evasion
from anti-tumour immunity. Here, I
will discuss novel therapeutic applications
of ICD for immunotherapy of glioblastoma
and delineate novel molecular
mechanisms underlying the ICD core
machinery.
|
|